Healthcare
Entrada Therapeutics, Inc.(TRDA)
Live Price
Offline$7.09
+4.11% today
1Y Change
-9.27%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $560.00M
- Revenue Growth
- -87.9%
- EPS Growth
- -297.2%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Entrada Therapeutics, Inc. (TRDA) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $7.09 and down 9.3% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -87.9%, EPS growth of -297.2%, a dividend yield of 0.0%. What stands out right now is revenue -87.9%, EPS -297.2%, free cash flow -189.7% with operating margin -621.1% and ROIC -44.2%. Valuation already assumes a fairly strong business story at price/sales 22.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TRDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-87.9% vs +7.6% peer median
Operating Margin
Below sector median
-621.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -87.9% and EPS is at -297.2%, with operating margin around -621.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.6% | -7.6% | -5.4% |
2026 Feb 26, 2026 | +28.8% | -6.7% | -9.1% | -3.8% |
2025 Nov 6, 2025 | -1.9% | -0.6% | +26.3% | +48.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRDA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRDA Max Drawdown
-64.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRDA and SPY.
Company Overview
Entrada Therapeutics, Inc.
NASDAQ Global Market
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Leadership
- Dipal Doshi
- IPO Date
- Oct 29, 2021
- Employees
- 183
- Street Address
- 6 Tide Street
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 520 9158
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 22.1
- Price/Book
- 2.0
Growth
- Revenue
- -87.9%
- EPS
- -297.2%
- Free Cash Flow
- -189.7%
Profitability
- Gross Margin
- -54.4%
- Operating Margin
- -621.1%
- Net Margin
- -565.5%
- ROE
- -39.8%
- ROIC
- -44.2%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 12.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.